As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

In August 2024, Eli Lilly announced that Zepbound would be available on its online pharmacy, LillyDirect, providing a new Zepbound self-pay option. The Zepbound LillyDirect offers comes in a ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound ... and the new prices, $399 or $549 a month, are still prohibitive for ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

The opportunity for Eli Lilly is significant, according to Leerink analyst David Risinger, who estimated in a Wednesday note that the move could add more than 3.7 million new Zepbound ...

The FDA's approval of Zepbound provides a new approach to treatment for Americans who struggle with OSA and obesity. Patients considering Zepbound should discuss the potential benefits ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, according to the chief executive officer of Zealand Pharma A/S ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable prescription medication ...